B. Pro

发表

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.

R. Advani, P. Bierman, L. Gordon, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

C. Elmets, J. Scarisbrick, P. Zinzani, 2018, The Lancet. Oncology.

Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma

B. Coiffier, S. Horwitz, H. Prince, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeting CD30 in Anaplastic Large Cell Lymphoma

B. Pro, J. Vadakara, Joseph Vadakara, 2012, Current Hematologic Malignancy Reports.

Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.

Y. Zu, Hao Liu, H. Heslop, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐Hodgkin lymphomas

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2013, British journal of haematology.

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma

G. Ayers, E. Jabbour, A. Younes, 2007, Cancer.

Hodgkin's Disease in Patients Infected with Human Immunodeficiency Virus: Frequency, Presentation and Clinical Outcome

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Leukemia & lymphoma.

Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma

Dan Jones, Maria A. Rodriguez, P. Mclaughlin, 2007, British journal of haematology.

Current management of peripheral T-cell lymphomas.

R. Rhoades, B. Pro, M. Gooptu, 2015, Cancer treatment and research.

Peripheral T-Cell Lymphomas: A Review of Current Approaches and Hopes for the Future

B. Pro, A. Skarbnik, M. Burki, 2013, Front. Oncol..

Current treatment of peripheral T-cell lymphoma.

B. Coiffier, S. Horwitz, E. Hsi, 2011, Clinical advances in hematology & oncology : H&O.

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B‐cell non‐Hodgkin lymphoma

Michael L. Wang, Maria A. Rodriguez, P. Mclaughlin, 2007, British journal of haematology.

Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.

Terry L. Smith, Maria A. Rodriguez, P. Mclaughlin, 2003, Oncology reports.

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.

Michael L. Wang, Maria A. Rodriguez, P. Mclaughlin, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy

P. Mclaughlin, F. Cabanillas, J. Cox, 2003, Cancer.

Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy

B. Pro, A. Mina, C. Vakkalagadda, 2019, Cancers.

Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.

J. Shah, W. Murphy, P. Mclaughlin, 2013, Clinical lymphoma, myeloma & leukemia.

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

B. Esmaeli, P. Mclaughlin, F. Cabanillas, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Emerging Immunotherapy Approaches in Peripheral T‐cell Lymphomas

B. Pro, A. Shustov, 2021 .

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.

E. Shpall, P. Mclaughlin, J. Manning, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab vedotin in Hodgkin's lymphoma

B. Pro, G. Perini, 2012, Expert opinion on biological therapy.

Therapeutic Response to Octreotide in Patients with Refractory CPT-11 Induced Diarrhea

J. Ajani, B. Pro, R. Lozano, 2001, Investigational New Drugs.

Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials

B. Coiffier, S. Bates, S. Horwitz, 2017, Leukemia & lymphoma.

Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma.

R. Advani, L. Gordon, J. Winter, 2020, Blood.

Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.

P. Mclaughlin, N. Ueno, L. Fayad, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.

P. Mclaughlin, A. Younes, L. Fayad, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

Maria A. Rodriguez, Y. Oki, Ying Yuan, 2012, Blood.

Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.

A. Younes, L. Fayad, B. Pro, 2006, Blood.

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

Y. Oki, P. Mclaughlin, A. Younes, 2008, Cancer.

Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins’ Lymphoma in First Remission

B. Pro, Manish Sharma, 2015, Current Treatment Options in Oncology.

Brentuximab Vedotin in CD30+ Lymphomas

B. Pro, G. Perini, 2013, Biologics in therapy.

Recent advances in the treatment of T-cell lymphoma.

B. Pro, 2011, Clinical advances in hematology & oncology : H&O.

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

K. Savage, F. Morschhauser, L. Trümper, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study.

M. Federico, C. Gisselbrecht, S. Horwitz, 2020, Clinical lymphoma, myeloma & leukemia.

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

R. Advani, Sonali M. Smith, A. Tulpule, 2019, Cancer.

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.

R. Advani, S. Horwitz, T. Illidge, 2018, Blood.

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

R. Advani, J. Connors, T. Illidge, 2017, Blood.

Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting

J. Connors, A. Younes, A. Engert, 2016, Clinical trials.

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.

Michael L. Wang, Y. Oki, P. Mclaughlin, 2015, Clinical lymphoma, myeloma & leukemia.

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T‐cell lymphoma

Michael L. Wang, Y. Oki, P. Mclaughlin, 2015, British Journal of Haematology.

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.

R. Advani, S. Horwitz, T. Illidge, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma

Y. Oki, Jiexin Zhang, Shouhao Zhou, 2013, Clinical Cancer Research.

Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T‐cell lymphoma

Y. Oki, P. Mclaughlin, A. Younes, 2013, British journal of haematology.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas

B. Pierce, Nidhi Sahni, R. Gowthaman, 2020, Nature Communications.

Kaposi sarcoma mimicking multiple cherry angiomata clinically and histologically in a patient with Sezary syndrome: an unusual presentation.

B. Pro, O. Alpdogan, Joya Sahu, 2015, Clinical lymphoma, myeloma & leukemia.

NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

M. Dwyer, A. Goodman, S. Ansell, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.

M. Dwyer, S. Ansell, Hema M Sundar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Racial differences in chronic lymphocytic leukemia

C. Flowers, B. Pro, 2013, Cancer.

Marginal zone lymphomas

P. Iyengar, P. Mclaughlin, F. Cabanillas, 2010, Cancer.

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

S. Verstovsek, N. Dang, R. Champlin, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2010, British journal of haematology.

Gallium Scan after the Second and Fourth Chemotherapy Cycle is Predictive in Aggressive Non-Hodgkin ’ s Lymphomas

Maria A. Rodriguez, D. Podoloff, P. Mclaughlin, 2012 .

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial

Y. Oki, L. Medeiros, A. Younes, 2016, Leukemia & lymphoma.

Non-Hodgkin's Lymphomas, version 3.2012.

J. Byrd, R. Advani, J. Vose, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Lymphoma Affecting the Central Nervous System

B. Pro, 2007 .

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.

Scott E. Smith, Eric Lester, Theodore Karrison, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab and palliative radiotherapy in 2 cases of refractory mycosis fungoides

J. Mehta, J. Guitart, B. Mittal, 2020, JAAD case reports.

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.

L. Medeiros, C. Tam, U. Popat, 2009, Blood.

Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma

P. Mclaughlin, A. Younes, L. Kwak, 2019, British journal of haematology.

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low‐grade B‐cell lymphomas

P. Mclaughlin, A. Younes, L. Kwak, 2015, British journal of haematology.

Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma.

P. Mclaughlin, L. Kwak, L. Fayad, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2014 .

Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.

B. Coiffier, C. Haioun, S. Horwitz, 2012, Clinical lymphoma, myeloma & leukemia.

Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes

B. Pro, Pamela Blair Allen, 2020, Current Oncology Reports.

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry

R. Advani, Sonali M. Smith, A. Tulpule, 2019, Acta Haematologica.

Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma

B. Coiffier, S. Horwitz, L. Sokol, 2016, Cancer medicine.

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

B. Coiffier, S. Horwitz, H. Prince, 2014, Journal of Hematology & Oncology.

Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

Maria A. Rodriguez, P. Mclaughlin, S. Neelapu, 2020, Leukemia & lymphoma.

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma

Michael L. Wang, Y. Oki, H. Kantarjian, 2018, Cancer.

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma

B. Coiffier, S. Horwitz, H. Prince, 2016, Hematological oncology.

Utility of 18 ﬂ uoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma

er, F. Morschhauser, S. Horwitz, 2015 .

90Y‐ibritumomab tiuxetan radiotherapy as first‐line therapy for early stage low‐grade B‐cell lymphomas, including bulky disease

P. Mclaughlin, L. Kwak, R. Mathur, 2014, British journal of haematology.

transplantation strategy in mantle cell lymphoma Mature results of the M. D. Anderson Cancer Center risk-adapted

L. Medeiros, C. Tam, U. Popat, 2013 .

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.

P. Mclaughlin, F. Cabanillas, M. Overman, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.

Michael L. Wang, A. Younes, L. Fayad, 2006, European journal of cancer.

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2003, Blood.

Long-Term F ollow-Up o f a P rospective S tudy o f C ombined Modality T herapy f or S tage I -II I ndolent N on-Hodgkin's Lymphoma

Maria A. Rodriguez, L. Fuller, P. Mclaughlin, 2003 .

Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma

Maria A. Rodriguez, P. Mclaughlin, A. Younes, 2006, Leukemia & lymphoma.

Progression of Cutaneous T-Cell Lymphoma after dupilumab: Case review of 7 patients.

J. Silverberg, J. Guitart, B. Pro, 2020, Journal of the American Academy of Dermatology.

A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma

P. Mclaughlin, R. Martell, L. Fayad, 2007 .

Non-Hodgkin's lymphomas, version 1.2013.

J. Byrd, R. Advani, J. Vose, 2013, The Journal of the National Comprehensive Cancer Network.

Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas

R. Advani, S. Horwitz, T. Illidge, 2013 .

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma

L. Gordon, J. Winter, J. Chmiel, 2022, Blood advances.

The histological prevalence and clinical implications of folliculotropism and syringotropism in mycosis fungoides.

P. Porcu, I. Chervoneva, W. Shi, 2019, Chinese clinical oncology.

Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

B. Coiffier, S. Horwitz, H. Prince, 2011 .

Preliminary Results of a Phase I/II Trial of BBR-2778 (Pixantrone) in Combination with Fludarabine, Dexamethasone, and Rituximab (FPD-R) in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

L. Fayad, G. Cohen, B. Pro, 2004 .

Hepatosplenic T-cell lymphoma and TNF-α inhibitors

B. Pro, J. Pozadzides, 2009, Expert review of hematology.

Central nervous system prophylaxis in peripheral T-cell lymphoma.

B. Pro, G. Perini, 2010, Blood.

Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update

R. Advani, J. Connors, T. Illidge, 2011 .

Cutaneous T-Cell Lymphoma, a Novel Manifestation of PDGFRA-Rearranged Neoplasm.

J. Guitart, A. Behdad, Xinyan Lu, 2018, The American Journal of dermatopathology.

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.

P. Mclaughlin, R. Orlowski, C. Bueso-Ramos, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Michael L. Wang, R. Couch, P. Mclaughlin, 2006, The Journal of infectious diseases.

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.

L. Staudt, W. Chan, W. Wilson, 2022, Blood.

NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.

M. Dwyer, A. Goodman, S. Ansell, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

CD8+ mycosis fungoides: A low‐grade lymphoproliferative disorder

J. Guitart, B. Pro, R. Kantor, 2017, Journal of the American Academy of Dermatology.

Hodgkin lymphoma.

R. Advani, P. Bierman, L. Gordon, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study

Maria A. Rodriguez, F. Cabanillas, N. Dang, 2004 .

Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study.

F. Cabanillas, N. Dang, L. Fayad, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,

B. Andersson, U. Popat, Q. Bashir, 2011 .

Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center.

Michael L. Wang, C. Tam, U. Popat, 2007 .

A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Michael L. Wang, Y. Oki, P. Mclaughlin, 2004 .

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.

H. Kantarjian, S. Verstovsek, Xuelin Huang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

D. Podoloff, T. Manshouri, P. Mclaughlin, 2009 .

Progression of undiagnosed cutaneous lymphoma after anti–tumor necrosis factor‐alpha therapy

C. Querfeld, J. Guitart, S. Rosen, 2018, Journal of the American Academy of Dermatology.

Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)

R. Bociek, R. Martell, J. Kuruvilla, 2008 .

Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab.

P. Mclaughlin, L. Medeiros, A. Younes, 2005 .

A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States

R. Advani, Sonali M. Smith, A. Tulpule, 2017, Cancer.

Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry

M. Federico, C. Gisselbrecht, S. Horwitz, 2012 .

Transforming growth factor superfamily ligands and links to tumorigenesis

L. Platanias, B. Pro, I. Akpan, 2018, Leukemia & lymphoma.

Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma

J. Winter, Elizabeth Hamilton, B. Pro, 2022, British journal of haematology.

Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma.

B. Esmaeli, P. Mclaughlin, D. Roberts, 2007, Archives of ophthalmology.

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2016 .

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

B. Coiffier, S. Horwitz, S. Whittaker, 2014, Biomarker Research.

A Phase II StudyÂ of Sequential Pembrolizumab (PEM)Â FollowedÂ By AVD for Frontline TreatmentÂ of Classical Hodgkin Lymphoma (CHL): Quantifying Response FollowingÂ PEM MonotherapyÂ with FDG-PET-Derived Metabolic Tumor Volume and Total Lesion Glycolysis

R. Advani, A. Rademaker, L. Gordon, 2018, Blood.

Report of the 6th International Workshop on PET in lymphoma

I. Buvat, W. Oyen, B. Cheson, 2017, Leukemia & lymphoma.

CD26/dipeptidyl peptidase IV and its role in cancer.

N. Dang, B. Pro, Nam H. Dang, 2004, Histology and histopathology.

Safety and Efficacy of Bortezomib Plus ICE (BICE) for the Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma.

A. Younes, Yuan Ji, L. Fayad, 2007 .

Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes

Sonali M. Smith, J. Dancey, E. Vokes, 2008 .

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

D. Berry, S. Faria, L. Medeiros, 2011 .

MULTI‐CENTER PHASE II STUDY OF ROMIDEPSIN PLUS LENALIDOMIDE FOR PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA (PTCL)

L. Gordon, J. Winter, J. Ruan, 2021, Hematological Oncology.

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2010 .

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

Michael L. Wang, P. Mclaughlin, L. Kwak, 2010, British journal of haematology.

Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

Yuan Ji, Paolo Anderlini, A. Younes, 2011, British journal of haematology.

Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy

B. Coiffier, S. Horwitz, H. Prince, 2010 .

A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial

J. Vose, Sonali M. Smith, K. Savage, 2013 .

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas

R. Advani, S. Horwitz, T. Illidge, 2012 .

Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non‐Hodgkin lymphoma

J. Singer, L. Fayad, G. Cohen, 2011, Cancer.

Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma

P. Mclaughlin, F. Cabanillas, A. Younes, 2006, Leukemia & lymphoma.

CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate.

P. Mclaughlin, M. Duvic, B. Pro, 2008, Journal of the American Academy of Dermatology.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

R. Advani, J. Briones, G. Salles, 2019, The Lancet.

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

M. Weichenthal, R. Dummer, O. Akilov, 2017, The Lancet.

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

R. Advani, A. Nademanee, J. Friedberg, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines

J. Byrd, R. Advani, J. Vose, 2012 .

Outcomes Using Doxorubicin-Based Chemotherapy with or without Radiotherapy for Early-Stage Peripheral T-cell Lymphomas

F. Cabanillas, J. Cox, R. Wilder, 2002, Leukemia & lymphoma.

PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

B. Coiffier, S. Horwitz, N. Bartlett, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnosis, Risk Stratification, and Treatment of Peripheral T-Cell Lymphomas

B. Pro, William B Pearse, 2020, Cancer Journal.

Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry

M. Federico, C. Gisselbrecht, S. Horwitz, 2019, American journal of hematology.

Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease

I. Flinn, P. Mclaughlin, F. Cabanillas, 2004, Clinical Cancer Research.

Non-Hodgkin's lymphomas, version 1.2013.

J. Byrd, R. Advani, J. Vose, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation.

B. Leiby, U. Martinez-outschoorn, W. Kraft, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

K. Savage, B. Coiffier, C. Gisselbrecht, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

Michael L. Wang, J. Shah, M. Wang, 2013, Leukemia.

A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease.

U. Martinez-outschoorn, I. Chervoneva, W. Shi, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T time: Emerging and new therapies for peripheral T-cell lymphoma.

B. Pro, A. Mina, 2021, Blood reviews.

Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.

B. Leiby, F. Sotgia, M. Lisanti, 2017, Seminars in oncology.

Adenocarcinoma of the small bowel

M. Bonnen, J. Ajani, D. Suki, 2004, Cancer.

Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.

A. Bleyer, F. Cabanillas, L. Medeiros, 2002, Oncology.

Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status

L. Gordon, J. Winter, T. Taxter, 2019, Leukemia & lymphoma.

Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.

Terry L. Smith, L. Fuller, P. Mclaughlin, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

B. Coiffier, S. Horwitz, H. Prince, 2016, Journal of Hematology & Oncology.

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

B. Coiffier, S. Horwitz, S. Whittaker, 2014, Biomarker Research.

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Matthew Greenwood, Martin Wilhelm, B. Coiffier, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Venetoclax-rituximab ± bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma: CONTRALTO.

I. Flinn, W. Hiddemann, P. Zinzani, 2020, Blood.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

R. Advani, J. Connors, T. Illidge, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hepatosplenic T-cell lymphoma: A rare but challenging entity.

A. Behdad, B. Pro, Pamela Blair Allen, 2020, Blood.

Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).

Marc L. Mendillo, T. Boggon, Juhyun Kim, 2017, Blood.

Hemophagocytic Lymphohistiocytosis in Cutaneous T-Cell Lymphoma

J. Guitart, B. Pro, X. Zhou, 2018, JAMA dermatology.

Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database.

S. Montoto, L. Gordon, S. Pileri, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

Giovanni Martinelli, Stefano Luminari, Luigi Rigacci, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.

G. Ayers, S. Verstovsek, P. Mclaughlin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease.

F. Turturro, L. Medeiros, U. Popat, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma

B. Pro, A. Skarbnik, 2013, Expert review of hematology.

Prospective Management of Primary Testicular Lymphoma (PTL) with Doxorubicin-Based Chemotherapy, Prophylactic Intrathecal (IT) Methotrexate and Radiotherapy (RT), but without Rituximab: Results from IELSG.

F. Cavalli, M. Gospodarowicz, G. Rassidakis, 2006 .

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis

P. Zinzani, S. Horwitz, E. Jacobsen, 2021, Blood.

Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature

L. Fayad, M. Thompson, F. Hagemeister, 2007, American journal of hematology.

Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)

J. Radford, M. Gospodarowicz, D. Heo, 2014, British journal of haematology.

The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)

N. Pavlakis, J. Radford, Yeon-Hee Park, 2014, Leukemia & lymphoma.

Treatment of Benign Lymphoid Hyperplasia of the Orbit With Rituximab

B. Esmaeli, J. Manning, B. Pro, 2010, Ophthalmic plastic and reconstructive surgery.

Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy.

B. Esmaeli, P. Mclaughlin, B. Pro, 2007, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.

B. Pro, Imran Nizamuddin, C. Galvez, 2021, Seminars in hematology.

Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy

L. Gordon, J. Winter, S. Chowdhury, 2021, Blood.

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

N. Ueno, B. Andersson, A. Younes, 2005, Bone Marrow Transplantation.

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL

L. Gordon, J. Winter, S. Chowdhury, 2022, Blood advances.

Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial

Scott E. Smith, L. Gordon, J. Winter, 2021, Blood.

Experience with heat shock protein‐peptide complex 96 vaccine therapy in patients with indolent non‐Hodgkin lymphoma

Y. Oki, P. Srivastava, P. Mclaughlin, 2007, Cancer.

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience

M. Munsell, N. Ueno, B. Andersson, 2008, Haematologica.

Prognosis and Outcomes of Patients with Post-Transplant Lymphoproliferative Disorder: A Single Center Retrospective Review

L. Gordon, J. Winter, J. Friedewald, 2020 .

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

C. Elmets, R. Dummer, R. Cowan, 2019, Blood.

Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL)

R. Advani, Sonali M. Smith, A. Tulpule, 2014 .

A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas

Sonali M. Smith, L. Gordon, J. Winter, 2021, Leukemia & lymphoma.

T Cell Lymphoma: Relapsed Disease

B. Pro, 2017 .

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma (PTCL): final results from the T‐ cell consortium trial

R. Advani, Sonali M. Smith, K. Savage, 2016, British journal of haematology.

Meta–analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics

B. Esmaeli, P. Mclaughlin, D. Roberts, 2007, Cancer.

R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

P. Mclaughlin, A. Younes, L. Kwak, 2008 .

Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL).

P. Mclaughlin, F. Cabanillas, N. Dang, 2005 .

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

K. Savage, P. Zinzani, S. Horwitz, 2022, Blood advances.

Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma.

L. Fayad, R. Nunez, F. Hagemeister, 2006 .

Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2016, British journal of haematology.

Angioimmunoblastic T-Cell Lymphoma: Still a dismal prognosis with current treatment approaches

P. Mclaughlin, B. Pro, 2007, Leukemia & lymphoma.

Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL).

P. Mclaughlin, A. Younes, L. Fayad, 2005 .

New molecular targets for treatment of lymphoma

A. Younes, B. Pro, 2004, Current oncology reports.

Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2003, Cancer.

Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.

S. Verstovsek, S. O'brien, L. Kwak, 2006 .

A phase II study of Epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin’s lymphomas

E. Vokes, T. Karrison, P. Stiff, 2005 .

Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

P. Porcu, U. Martinez-outschoorn, N. Flomenberg, 2020, Leukemia & lymphoma.

Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma

L. Gordon, J. Winter, B. Pro, 2022, EJHaem.

Revalidation of FLIPI in patients with follicular lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy

A. López-Guillermo, S. Pileri, M. Federico, 2007 .

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma

Y. Oki, P. Mclaughlin, A. Younes, 2014, British journal of haematology.

Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma

F. Cabanillas, J. Cox, R. Wilder, 2001, Cancer.

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

R. Bociek, P. Mclaughlin, A. Younes, 2007 .

Women’s Representation in Leadership Positions in Academic Medical Oncology, Radiation Oncology, and Surgical Oncology Programs

M. Knoll, K. Patel, N. Vapiwala, 2020, JAMA network open.

Analysis of Peripheral T‐cell Lymphoma Diagnostic Workup in the United States

R. Advani, Sonali M. Smith, A. Tulpule, 2017, Clinical lymphoma, myeloma & leukemia.

Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL).

B. Coiffier, S. Horwitz, H. Prince, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens

K. Savage, H. Borghaei, E. Jacobsen, 2010 .

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

C. Gisselbrecht, S. Horwitz, N. Bartlett, 2010 .

Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL).

P. Mclaughlin, D. Schenkein, L. Fayad, 2004, Journal of Clinical Oncology.

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results

P. Zinzani, S. Horwitz, S. Lustgarten, 2020 .

Integrated Genomic Analyses of Cutaneous T Cell Lymphomas Reveal the Molecular Bases for Disease Heterogeneity.

P. Kwok, J. Sosman, T. Boggon, 2021, Blood.

Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.

Scott E. Smith, L. Gordon, J. Winter, 2023, JAMA oncology.

Results of a Phase II Study of 506U78 (Nelarabine) in Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma.

A. Bleyer, F. Cabanillas, A. Sarris, 2005 .

A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma.

F. Cabanillas, N. Dang, E. Grimm, 2004, Journal of Clinical Oncology.

PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma

K. Savage, B. Coiffier, P. Zinzani, 2008 .

ABVD with Pegfilgrastim (Neulasta) Support in Newly Diagnosed Hodgkin Lymphoma: Long-Term Safety and Efficacy Results of a Phase-II Study.

Michael L. Wang, A. Younes, L. Fayad, 2005 .

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

A. Zelenetz, P. Mclaughlin, L. Fayad, 2010 .

Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas

B. Pierce, Nidhi Sahni, R. Gowthaman, 2020, Nature Communications.

Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma

B. Leber, P. Mclaughlin, A. Younes, 2008, British journal of haematology.

Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices

L. Gordon, J. Winter, S. Chowdhury, 2021, Blood.

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2004 .

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen

L. Gordon, J. Winter, A. Evens, 2020 .

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

B. Coiffier, S. Horwitz, J. Wolfson, 2017, Journal of Hematology & Oncology.

Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T-cell lymphoma.

J. Vose, K. Savage, L. de Leval, 2023, Hematological oncology.

Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL)

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2008 .

Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data

P. Zinzani, M. Crump, I. Fleury, 2016 .

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

R. Advani, K. Savage, S. Horwitz, 2021, Blood.

Oblimersen sodium (Bcl-2 antisense) plus rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma: Preliminary phase II results

P. Mclaughlin, L. Fayad, A. Goy, 2004 .

Thalidomide for patients with recurrent lymphoma

P. Mclaughlin, F. Cabanillas, M. Albitar, 2004, Cancer.

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

Sonali M. Smith, L. Gordon, J. Winter, 2019, Blood.

Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.

Michael L. Wang, D. Podoloff, P. Mclaughlin, 2007 .

Second-line 90Yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab.

B. Esmaeli, B. Pro, F. Samaniego, 2012, Ophthalmic plastic and reconstructive surgery.

Safety and Efficacy of Bortezomib (Velcade) for the Treatment of Relapsed Classical Hodgkin’s Disease.

A. Younes, N. Dang, B. Pro, 2004 .

The lymphomas: molecular pathways and novel therapeutic targets.

A. Younes, B. Pro, A. Wedgwood, 2005, Current hematology reports.

Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival.

S. Horwitz, E. Jacobsen, O. O’Connor, 2010 .

Stem Cell Transplant (SCT) and Pralatrexate Therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Who Received SCT Prior to or Following Pralatrexate Therapy.

S. Horwitz, E. Jacobsen, O. O’Connor, 2009 .

Phase II study of oxaliplatin in patients with recurrent or refractory non‐Hodgkin lymphoma

A. Bleyer, Y. Oki, P. Mclaughlin, 2005, Cancer.

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

R. Advani, K. Savage, P. Zinzani, 2019, Blood.

Identifying and addressing unmet clinical needs in primary cutaneous B-cell lymphoma: A consensus-based paper from an ad-hoc international panel.

S. Swerdlow, S. Pileri, L. Cerroni, 2023, Hematological oncology.

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

R. Advani, K. Savage, P. Zinzani, 2020 .

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

S. Horwitz, E. Jacobsen, H. Youssoufian, 2019, Blood.

984TiPPHASE 3 TRIAL OF BRENTUXIMAB VEDOTIN AND CHP VERSUS CHOP IN THE FRONTLINE TREATMENT OF PATIENTS (PTS) WITH CD30+ MATURE T-CELL LYMPHOMAS (MTCL).

L. Trümper, T. Illidge, B. Pro, 2014, Annals of Oncology.

How I Treat Post-Transplant Lymphoproliferative Disorder.

B. Pro, J. Amengual, 2023, Blood.

Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.

P. Mclaughlin, A. Younes, L. Kwak, 2005 .

PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31)

A. López-Guillermo, S. Montoto, L. Mazzucchelli, 2021, Hematological Oncology.

Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF)

K. Savage, B. Coiffier, S. Horwitz, 2010 .

Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides

J. Guitart, B. Pro, N. Mehta-Shah, 2021, Journal of Drugs in Dermatology.

Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data.

P. Mclaughlin, A. Younes, L. Fayad, 2009 .

Non-Hodgkin's lymphomas.

J. Byrd, R. Advani, J. Vose, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Michael L. Wang, P. Mclaughlin, L. Kwak, 2008 .

Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Michael L. Wang, Y. Oki, D. Podoloff, 2006 .

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

C. Elmets, J. Scarisbrick, P. Zinzani, 2018, The Lancet. Oncology.

International prognostic index‐based outcomes for diffuse large B‐cell lymphomas

S. Tucker, F. Cabanillas, L. Medeiros, 2002, Cancer.

Marginal zone lymphomas

P. Iyengar, P. Mclaughlin, F. Cabanillas, 2010, Cancer.

Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2016, British journal of haematology.

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.

L. Medeiros, C. Tam, U. Popat, 2009, Blood.

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael L. Wang, A. Younes, J. Zeldis, 2008 .

Conditioning regimens Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

N. Ueno, B. Andersson, L. Fayad, 2005 .

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2006 .

A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.

N. Bartlett, L. Sokol, D. Hurd, 2006 .

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.

Michael L. Wang, Y. Oki, P. Mclaughlin, 2015, Clinical lymphoma, myeloma & leukemia.

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma

Y. Oki, Jiexin Zhang, Shouhao Zhou, 2013, Clinical Cancer Research.

Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma

L. Gordon, J. Winter, B. Jovanovic, 2023, Blood advances.

Phase II study of oblimersen sodium and rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma

B. Leber, P. Mclaughlin, A. Younes, 2005 .

Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy.

P. Mclaughlin, A. Younes, L. Fayad, 2007 .

Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non‐Hodgkin lymphoma

J. Singer, L. Fayad, G. Cohen, 2011, Cancer.

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 2009 .

Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment

M. Federico, C. Gisselbrecht, S. Horwitz, 2012 .

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

R. Advani, J. Connors, T. Illidge, 2012 .

The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone

P. Mclaughlin, F. Cabanillas, M. Overman, 2007 .

Bone Loss in Lymphoma Patients Prior to Receiving Front-line Therapy

W. Murphy, P. Mclaughlin, L. Kwak, 2010 .

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

R. Advani, J. Connors, T. Illidge, 2017, Blood.

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

B. Esmaeli, P. Mclaughlin, F. Cabanillas, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

P. Mclaughlin, L. Kwak, L. Fayad, 2009 .

Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Final Analysis of Phase II CONTRALTO Study

I. Flinn, W. Hiddemann, P. Zinzani, 2018, Blood.

Hepatosplenic gamma-delta T-cell lymphoma, disseminated intravascular coagulation, and systemic mastocytosis: an unusual presentation for a rare disease.

B. Pro, G. Perini, 2010, Clinical advances in hematology & oncology : H&O.